Crossmark

CD226: a potent driver of antitumor immunity that needs to be maintained

Crossref DOI link: https://doi.org/10.1038/s41423-020-00633-0

Published Online: 2021-01-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Bi, Jiacheng https://orcid.org/0000-0001-5646-0119
License Information

Text and Data Mining valid from 2021-01-08

Version of Record valid from 2021-01-08
More Information

Article History

Received: 15 December 2020

Accepted: 16 December 2020

First Online: 8 January 2021

Competing interests

: The author declares no competing interests.